Cardiff Oncology (NASDAQ:CRDF) Upgraded to “Hold” at Wall Street Zen

Cardiff Oncology (NASDAQ:CRDF) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Wednesday.

A number of other brokerages have also recently weighed in on CRDF. Piper Sandler dropped their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Noble Financial assumed coverage on shares of Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Stock Down 2.6%

NASDAQ:CRDF opened at $1.89 on Wednesday. Cardiff Oncology has a 52 week low of $1.48 and a 52 week high of $4.56. The stock’s fifty day moving average is $2.28 and its two-hundred day moving average is $2.24. The company has a market capitalization of $129.20 million, a P/E ratio of -2.74 and a beta of 1.32.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%. Sell-side analysts anticipate that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jeppson Wealth Management LLC purchased a new position in Cardiff Oncology in the third quarter valued at $25,000. Brooklyn Investment Group acquired a new position in shares of Cardiff Oncology during the 3rd quarter worth about $26,000. Capital Advisors Wealth Management LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at about $30,000. Tamar Securities LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at about $32,000. Finally, R Squared Ltd acquired a new stake in shares of Cardiff Oncology during the 4th quarter worth about $36,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.